Brief: HLS Therapeutics Q4 2018 Revenue Was $16.7 Mln Compared To $20.4 Mln In Q4 2017
21/03/2019 10:42
March 21 (Reuters) - HLS Therapeutics Inc HLS.TO :
* HLS THERAPEUTICS ANNOUNCES Q4 AND YEAR-END 2018 FINANCIAL
RESULTS
* Q4 2018 REVENUE WAS $16.7 MILLION COMPARED TO $20.4
MILLION IN
Q4 2017
* Q4 2018 NET INCOME OF $0.4 MILLION, OR $0.01 PER COMMON
SHARE
* Q4 2018 ADJUSTED EBITDA WAS $11.2 MILLION COMPARED TO
$15.5
MILLION IN Q4 2017
Source text for Eikon: ID:nCNWYBYYca
Further company coverage: HLS.TO
(((Reuters.Briefs@thomsonreuters.com);;))
Recent news on HLS Therapeutics
See all newsCanada Research Roundup: CIBC ,HLS Therapeutics, TD Bank Group
Canada's HLS Therapeutics Q1 revenue rises on Vascepa growth, reaffirms 2026 guidance
Canada's HLS Therapeutics Q4 revenue slightly beats on Vascepa strength
Brief: Esperion Partner announces HLS Therapeutics received approval Of NILEMDO for the reduction of LDL-cholesterol in canadians at risk of cardiovascular disease
Brief: HLS Therapeutics announces Health Canada approval of NILEMDO for the reduction of LDL-Cholesterol in Canadians at risk of cardiovascular disease